IP Verse

Nucleic Acid Vaccines - EP3134131

The patent EP3134131 was granted to Moderna on Dec 22, 2021. The application was originally filed on Apr 23, 2015 under application number EP15783606A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3134131

MODERNA
Application Number
EP15783606A
Filing Date
Apr 23, 2015
Status
Granted And Under Opposition
Nov 19, 2021
Grant Date
Dec 22, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BIONTECHSep 22, 2022WILKADMISSIBLE
PFIZERSep 22, 2022EDERADMISSIBLE
SEQIRUS UKSep 21, 2022CARPMAELS & RANSFORDADMISSIBLE
WITHERS & ROGERSSep 16, 2022TOMBLINGWITHDRAWN
SANOFISep 13, 2022CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (74) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2012116810
INTERNATIONAL-SEARCH-REPORTUS2008057080
INTERNATIONAL-SEARCH-REPORTUS8658354
INTERNATIONAL-SEARCH-REPORTWO2008143640
INTERNATIONAL-SEARCH-REPORTWO2010148013
INTERNATIONAL-SEARCH-REPORTWO2013090186
INTERNATIONAL-SEARCH-REPORTWO2013143555
OPPOSITIONEP2791160
OPPOSITIONEP2964608
OPPOSITIONEP3083579
OPPOSITIONUS2008057080
OPPOSITIONUS2012177701
OPPOSITIONUS2013245107
OPPOSITIONUS2013266640
OPPOSITIONUS8470771
OPPOSITIONUS8658354
OPPOSITIONUS9364435
OPPOSITIONWO2007024708
OPPOSITIONWO2007051303
OPPOSITIONWO2008143640
OPPOSITIONWO2008145129
OPPOSITIONWO2009127060
OPPOSITIONWO2010037539
OPPOSITIONWO2010088927
OPPOSITIONWO2010148013
OPPOSITIONWO2011005799
OPPOSITIONWO2011068810
OPPOSITIONWO2011071931
OPPOSITIONWO2011127255
OPPOSITIONWO2012006369
OPPOSITIONWO2012006372
OPPOSITIONWO2012006377
OPPOSITIONWO2012019168
OPPOSITIONWO2012030901
OPPOSITIONWO2012031046
OPPOSITIONWO2012045075
OPPOSITIONWO2012092569
OPPOSITIONWO2012116810
OPPOSITIONWO2012135805
OPPOSITIONWO2012158736
OPPOSITIONWO2012170889
OPPOSITIONWO2012170930
OPPOSITIONWO2013052523
OPPOSITIONWO2013075266
OPPOSITIONWO2013090186
OPPOSITIONWO2013090648
OPPOSITIONWO2013143555
OPPOSITIONWO2013151663
OPPOSITIONWO2013151664
OPPOSITIONWO2013151665
OPPOSITIONWO2013151666
OPPOSITIONWO2013151667
OPPOSITIONWO2013151668
OPPOSITIONWO2013151669
OPPOSITIONWO2013151670
OPPOSITIONWO2013151671
OPPOSITIONWO2013151672
OPPOSITIONWO2013151736
OPPOSITIONWO2013185069
OPPOSITIONWO2014081507
OPPOSITIONWO2014093574
OPPOSITIONWO2014152211
OPPOSITIONWO2014152540
OPPOSITIONWO2014159813
OPPOSITIONWO2015006747
OPPOSITIONWO2015023461
OPPOSITIONWO2015048744
OPPOSITIONWO2015164674
SEARCHUS2013266640
SEARCHWO2007051303
SEARCHWO2009127060
SEARCHWO2012030901
SEARCHWO2013075266
SEARCHWO2013185069

Non-Patent Literature (NPL) Citations (57) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Benjamin Petsch ET AL, "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nature Biotechnology, (20120101), vol. 30, no. 12, doi:10.1038/nbt.2436, ISSN 1087-0156, pages 1210 - 1216, XP055051005
OPPOSITION- Anonymous, "Measles morbillivirus", Wikipedia, (20231228), pages 1 - 6, Wikipedia, URL: https://en.wikipedia.org/w/index.php?title=Measles_morbillivirus&oldid=1192195247, XP093160170-
OPPOSITION- Anonymous , "RecName: Full=Hemagglutinin {ECO:0000256|HAMAP-Rule:MF_04072};", Uniprot, (20140903), Database accession no. A0A059T4A1, XP055970072-
OPPOSITION- "Influenza A virus (A/Jiangxi/IPB13/2013(H10N8)) segment 4 hemagglutinin (HA) gene, complete cds", NUCLEOTIDE, NCBI, (20140612), Database accession no. KJ406543 , XP055232578-
OPPOSITION- Jeremy M. Berg, John L. Tymoczko, Lubert Stryer, "Chapter 4: DNA, RNA, and the Flow of Genetic Information", Jeremy M. Berg, John L. Tymoczko, Lubert Stryer, Jeremy M. Berg, John L. Tymoczko, Lubert Stryer, Biochemistry. Sixth Ed., New York, W.H. Freeman, (20070101), pages 107 - 133, ISBN 0-7167-8724-5, XP009552806-
OPPOSITION- Karikó Katalin; Weissman Drew, "Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development.", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, GB , (20070101), vol. 10, no. 5, ISSN 1367-6733, pages 523 - 532, XP009154595-
OPPOSITION- Ryan Cross, "Without these lipid shells, there would be nomRNA vaccines for COVID-19", C& en, (20210306), vol. 99, no. 8, XP055972666-
OPPOSITION- MUTHUSAMY et al., "Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo", Angew. Chem., (20120820), vol. 51, doi:10.1002/anie.201203263, pages 8529 - 8533, XP055063645
OPPOSITION- FREDERIC MARTINON et al., "Induction of virus- specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", Eur. J. Immunol., (19930700), vol. 23, pages 1719 - 1722, XP002660045
OPPOSITION- KRAMPS et al., "Messenger RNA-based vaccines: progress, challenges, applications", WIREs RNA, (20130000), vol. 4, doi:10.1002/wrna.1189, pages 737 - 749, XP055180522
OPPOSITION- Atsmon et al., "Safety and Immunogenicity of Multimeric-001 - a Novel Universal Influenza Vaccine", J Clin Immunol, (2012), vol. 32, doi:10.1007/s10875-011-9632-5, XP035054835
OPPOSITION- KAUFFMAN KJ et al., "Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo", Biomaterials, (20150925), vol. 109, doi:10.1016/j.biomaterials.2016.09.006, pages 78 - 87, XP055660212
OPPOSITION- Houser Katherine; Subbarao Kanta, "Influenza Vaccines: Challenges and Solutions", Cell Host & Microbe, Elsevier, NL, NL , (20150311), vol. 17, no. 3, doi:10.1016/j.chom.2015.02.012, ISSN 1931-3128, pages 295 - 300, XP029145223
OPPOSITION- Mendonça Monique C P, Kont Ayse, Kowalski Piotr S, O'driscoll Caitriona M, "Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids", Drug Discovery Today, (20230301), vol. 28, no. 3, doi:10.1016/j.drudis.2023.103505This, XP093117436
OPPOSITION- KATALIN KARIKO et al., "Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA", Immunity, (20050800), vol. 23, doi:10.1016/j.immuni.2005.06.008, pages 165 - 175, XP055548954
OPPOSITION- Karikó K, Buckstein M, Ni H, Weissman D, "Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20050801), vol. 23, no. 2, doi:10.1016/J.IMMUNI.2005.06.008, ISSN 1074-7613, pages 165 - 175, XP002634064
OPPOSITION- HASHIBA A et al., "The use of design of experiments with multiple responses to determine optimal formulations for in vivo hepatic mRNA delivery", J Control Release., (20200825), vol. 327, doi:10.1016/j.jconrel.2020.08.031, pages 467 - 476, XP086327838
OPPOSITION- Geall Andrew J.; Mandl Christian W.; Ulmer Jeffrey B., "RNA: The new revolution in nucleic acid vaccines", Seminars in immunology, W.B. SAUNDERS COMPANY, PA., US, US , (19000101), vol. 25, no. 2, doi:10.1016/j.smim.2013.05.001, ISSN 1044-5323, pages 152 - 159, XP028694558
OPPOSITION- Juine-Ruey Chen; Che Ma; Chi-Huey Wong;, "Vaccine design of hemagglutinin glycoprotein against influenza", TRENDS IN BIOTECHNOLOGY., ELSEVIER PUBLICATIONS, CAMBRIDGE., GB, GB , vol. 29, no. 9, doi:10.1016/j.tibtech.2011.04.007, ISSN 0167-7799, pages 426 - 434, XP028383329
OPPOSITION- Ellebedy, A.H. ; Webby, R.J., "Influenza vaccines", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20091105), vol. 27, doi:10.1016/j.vaccine.2009.08.038, ISSN 0264-410X, pages D65 - D68, XP026694007
OPPOSITION- KAUFFMAN KJ et al., "Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs", Nano Lett., (20151111), vol. 15, no. 11, doi:10.1021/acs.nanolett.5b02497, pages 7300 - 6, XP055679418
OPPOSITION- Armin Hekele, Bertholet Sylvie, Archer Jacob, Gibson Daniel G, Palladino Giuseppe, Brito Luis A, Otten Gillis R, Brazzoli Michela, Buccato Scilla, Bonci Alessandra, Casini Daniele, Maione Domenico, Qi Zhi-Qing, Gill John E, Caiazza Nicky C, Urano Jun, Hubby Bolyn, Gao George F, Shu Yuelong, De Gregorio Ennio, Mandl Christian W, Mason Peter W, Settembre Ethan C, Ulmer Jeffrey B, Craig Venter J, Dormitzer Philip R, Rappuoli Rino, Geall Andrew J, "Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice", Emerging Microbes & Infections, (20130801), vol. 2, no. 8, doi:10.1038/emi.2013.54, page e52, XP055397456
OPPOSITION- KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556
OPPOSITION- Karikó Katalin, Muramatsu Hiromi, Welsh Frank A, Ludwig János, Kato Hiroki, Akira Shizuo, Weissman Drew, "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability /NIH Author Manuscript/", Molecular Therapy, Elsevier Inc., US, US , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0016, pages 1833 - 1840, XP055920956
OPPOSITION- Karikó K, Muramatsu H, Keller J M, Weissman D., "Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.", Molecular Therapy, Nature Publishing Group, GB, GB , (20120501), vol. 20, no. 5, doi:10.1038/mt.2012.7, ISSN 1525-0024, pages 948 - 953, XP002696191
OPPOSITION- Sean C Semple, Akin Akinc, Jianxin Chen, Ammen P Sandhu, Barbara L Mui, Connie K Cho, Dinah W Y Sah, Derrick Stebbing, Erin J Crosley, Ed Yaworski, Ismail M Hafez, J Robert Dorkin, June Qin, Kieu Lam, Kallanthottathil G Rajeev, Kim F Wong, Lloyd B Jeffs, Lubomir Nechev, Merete L Eisenhardt, Muthusamy Jayaraman, Mikameh Kazem, Martin A Maier, Masuna Srinivasulu, Michael J Weinstein, Qingmin Chen, Rene Alvarez, Scott A Barros, Soma De, Sandra K Klimuk, Todd Borland, Verbena Kosovrasti, William L Cantley, Ying K Tam, Muthiah Manoharan, Marco A Ciufolini, Mark A Tracy, Antonin De Fougerolles, Ian Maclachlan, Pieter R Cullis, Thomas D Madden, Michael J Hope, "Rational design of cationic lipids for siRNA delivery", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20100201), vol. 28, no. 2, doi:10.1038/nbt.1602, ISSN 1087-0156, pages 172 - 176, XP055539273
OPPOSITION- Sean C Semple, Akin Akinc, Jianxin Chen, Ammen P Sandhu, Barbara L Mui, Connie K Cho, Dinah W Y Sah, Derrick Stebbing, Erin J Crosley, Ed Yaworski, et al., "Rational design of cationic lipids for siRNA delivery", Nature Biotechnology, Nature Publishing Group US, New York, New York, (20100201), vol. 28, no. 2, doi:10.1038/NBT.1602, ISSN 1087-0156, pages 172 - 176, XP002633693
OPPOSITION- Michael S D Kormann, Günther Hasenpusch, Manish K Aneja, Gabriela Nica, Andreas W Flemmer, Susanne Herber-Jonat, Marceline Huppmann, Lauren E Mays, Marta Illenyi, Andrea Schams, Matthias Griese, Iris Bittmann, Rupert Handgretinger, Dominik Hartl, Joseph Rosenecker, Carsten Rudolph, "Expression of therapeutic proteins after delivery of chemically modified mRNA in mice", Nature Biotechnology, Gale Group Inc., (20110201), vol. 29, no. 2, doi:10.1038/nbt.1733, ISSN 10870156, pages 154 - 157, XP055040839
OPPOSITION- Benjamin Petsch, Margit Schnee, Annette B Vogel, Elke Lange, Bernd Hoffmann, Daniel Voss, Thomas Schlake, Andreas Thess, Karl-Josef Kallen, Lothar Stitz, Thomas Kramps, "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nature Biotechnology, Gale Group Inc., (20120101), vol. 30, no. 12, doi:10.1038/nbt.2436, ISSN 10870156, pages 1210 - 1216, XP055051005
OPPOSITION- Sook-San Wong, Webby Richard J, "An mRNA vaccine for influenza", doi:10.1038/nbt.2439, (20121231), pages 1202 - 1204, URL: http://www.nature.com/nbt/journal/v30/n12/pdf/nbt.2439.pdf, (20170711), XP055389920
OPPOSITION- Ugur Sahin, Katalin Karikó, Özlem Türeci, "mRNA-based therapeutics — developing a new class of drugs", Nature Reviews Drug Discovery, Nature Pub. Group, vol. 13, no. 10, doi:10.1038/nrd4278, ISSN 14741776, pages 759 - 780, XP055159205
OPPOSITION- Hao Yin, Kanasty Rosemary L., Eltoukhy Ahmed A., Vegas Arturo J., Dorkin J. Robert, Anderson Daniel G., "Non-viral vectors for gene-based therapy", NATURE REVIEWS GENETICS, Nature Publishing Group, GB, GB , (20140715), vol. 15, no. 8, doi:10.1038/nrg3763, ISSN 1471-0056, pages 541 - 555, XP055240438
OPPOSITION- Cheng Qiang; Wei Tuo; Farbiak Lukas; Johnson Lindsay T.; Dilliard Sean A.; Siegwart Daniel J., "Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing", Nature Nanotechnology, Nature Pub. Group, Inc., London, London , (20200401), vol. 15, no. 4, doi:10.1038/s41565-020-0669-6, ISSN 1748-3387, pages 313 - 320, XP037096153
OPPOSITION- HOU, X. et al., "Lipid nanoparticles for mRNA delivery", Nat Rev, (20210000), vol. 6, doi:10.1038/s41578-021-00358-0, pages 1078 - 1094, XP037634156
OPPOSITION- MIAO L et al., "Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation", Nat Biotechnol., (20191000), pages 1174 - 118 5, XP036897247
OPPOSITION- CHOI J et al., "Puglisi JD. 2'-O-methylation in mRNA disrupts tRNA decoding during translation elongation", Nat Struct Mol Biol., (20180300), vol. 25, no. 3, pages 208 - 216, XP036447846
OPPOSITION- Andrew J. Geall, Ayush Verma, Gillis R. Otten, Christine A. Shaw, Armin Hekele, Kaustuv Banerjee, Yen Cu, Clayton W. Beard, Luis A. Brito, Thomas Krucker, Derek T. O�Hagan, Manmohan Singh, Peter W. Mason, Nicholas M. Valiante, Philip R. Dormitzer, Susan W. Barnett, Rino Rappuoli, Jeffrey B. Ulmer, Christian W. Mandl, "Nonviral delivery of self-amplifying RNA vaccines.", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20120904), vol. 109, no. 36, doi:10.1073/PNAS.1209367109, ISSN 0027-8424, pages 14604 - 14609, XP002683929
OPPOSITION- STEPHENSON I et al., "Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore /97 (H5N3) vaccine: a potential priming strategy", J Infect Dis., (20050314), vol. 191, no. 8, doi:10.1086/428948, pages 1210 - 5, XP002696222
OPPOSITION- Hemmer et al., "Minimal peptide length requirements for CD4+ T cell clones - implications for molecular mimicry and T cell survival", International Immunology, (2000), vol. 12, doi:10.1093/intimm/12.3.375, XP055523276
OPPOSITION- B. R. Anderson, H. Muramatsu, S. R. Nallagatla, P. C. Bevilacqua, L. H. Sansing, D. Weissman, K. Kariko, "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation", Nucleic Acids Research, Information Retrieval Ltd., (20100901), vol. 38, no. 17, doi:10.1093/nar/gkq347, ISSN 03051048, pages 5884 - 5892, XP055041208
OPPOSITION- B. R. Anderson, H. Muramatsu, B. K. Jha, R. H. Silverman, D. Weissman, K. Kariko, "Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L", Nucleic Acids Research, Information Retrieval Ltd., (20111101), vol. 39, no. 21, doi:10.1093/nar/gkr586, ISSN 03051048, pages 9329 - 9338, XP055126203
OPPOSITION- Karikó K, Muramatsu H, Ludwig J, Weissman D., "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.", Nucleic Acids research, Oxford University Press, GB, GB , (20111101), vol. 39, no. 21, doi:10.1093/nar/gkr695, ISSN 1362-4962, pages e142 - e142-10, XP002758752
OPPOSITION- HOERNES TP et al., "Nucleotide modifications within bacterial messenger RNAs regulate their translation and are able to rewire the genetic code", Nucleic Acids Res., (20160129), vol. 44, no. 2, doi:10.1093/nar/gkv1182, pages 852 - 62, XP055838402
OPPOSITION- Cox Manon M J; Patriarca Peter A; Treanor John, "FluBlok, a recombinant hemagglutinin influenza vaccine", Influenza and Other Respiratory Viruses, Blackwell Publishing Ltd, UK, UK , (20081101), vol. 2, no. 6, doi:10.1111/j.1750-2659.2008.00053.x, ISSN 1750-2640, pages 211 - 219, XP009132772
OPPOSITION- S.-S. Wong, R. J. Webby, "Traditional and New Influenza Vaccines", Clinical Microbiology Review, WASHINGTON, DC., US, US , (20130701), vol. 26, no. 3, doi:10.1128/CMR.00097-12, ISSN 0893-8512, pages 476 - 492, XP055704243
OPPOSITION- Peabody David S., Berg Paul, "Termination-reinitiation occurs in the translation of mammalian cell mRNAs", MOLECULAR AND CELLULAR BIOLOGY, American Society for Pharmacology and Experimental Therapeutics, US, US , (19860701), vol. 6, no. 7, doi:10.1128/MCB.6.7.2695, ISSN 0270-7306, pages 2695 - 2703, XP093117434
OPPOSITION- SCHUMANN U et al., "Multiple links between 5- methylcytosine content of mRNA and translation", BMC Biol., (20200415), vol. 18, no. 1, page 40, XP055972663
OPPOSITION- ALTIERI JAC et al., "The influence of 4-thiouridine labeling on pre-mRNA splicing outcomes", PLoS One, (20211213), vol. 16, no. 12, XP055972662
OPPOSITION- Deering Raquel P; Kommareddy Sushma; Ulmer Jeffrey B, "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.", Expert opinion on drug delivery, Informa Healthcare, UK, UK , (20140601), vol. 11, no. 6, doi:10.1517/17425247.2014.901308, ISSN 1744-7593, pages 885 - 899, XP009183535
OPPOSITION- Alicia Rodriguez-Gascon, Ana Del Pozo-Rodríguez, María Angeles Solinís, "Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles", International Journal of Nanomedicine, DOVE Medical Press, (20140401), doi:10.2147/IJN.S39810, ISSN 11769114, page 1833, XP055200967
OPPOSITION- Maria L. Guevara, Francesca Persano, Stefano Persano, "Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy", Frontiers in Chemistry, (20201023), vol. 8, doi:10.3389/fchem.2020.589959, pages 1 - 17, XP055764555
OPPOSITION- BUSCHMANN MD, "Nanomaterial Delivery Systems for mRNA Vaccines", V accines (Basel, (20210119), vol. 9, no. 1, doi:10.3390/vaccines9010065, page 65, XP055927791
OPPOSITION- Andreas M Reichmuth, Matthias A Oberli, Ana Jaklenec, Robert Langer, Daniel Blankschtein, "mRNA vaccine delivery using lipid nanoparticles", Therapeutic Delivery, Future Science Ltd., GB, GB , (20160501), vol. 7, no. 5, doi:10.4155/tde-2016-0006, ISSN 2041-5990, pages 319 - 334, XP055401839
OPPOSITION- KARL-JOSEF KALLEN et al., "A novel, disruptive vaccination technology", Human Vaccines & Immunotherapeutics, (20130604), vol. 9, no. 10, pages 2263 - 2276, XP055126357
OPPOSITION- Thomas Schlake, Andreas Thess, Mariola Fotin-Mleczek, Karl-Josef Kallen, "Developing mRNA-vaccine technologies", RNA BIOLOGY, (20121101), vol. 9, no. 11, doi:10.4161/rna.22269, ISSN 1547-6286, pages 1319 - 1330, XP055561756
SEARCH- ARMIN HEKELE ET AL, "Rapidly produced SAM? vaccine against H7N9 influenza is immunogenic in mice", EMERGING MICROBES & INFECTIONS, (20130801), vol. 2, no. 8, doi:10.1038/emi.2013.54, page e52, XP055397456 [I] 1-10,17-18 * Abstract;p. 2 "LNP/RNA f0ormulation" *
SEARCH- ANDREW J GEALL ET AL, "Nonviral delivery of self-amplifying RNA vaccines", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 109, no. 36, doi:10.1073/PNAS.1209367109, ISSN 0027-8424, (20120904), pages 14604 - 14609, (20120820), XP002683929 [I] 1-10,17-18 * Abstract; p. 14608 "LNP/RNA formulation" *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents